NKGen Biotech, Inc. /
NKMax Co., Ltd.
NKGen Biotech takes control of NKMax in completed acquisition
Source for the buyer and target: NKGen Biotech, Inc.
For the buyer and target.
“On September 4, 2025, NKGen Biotech, Inc. (the “Company”) completed the acquisition of a majority equity stake in NKMax Co., Ltd. (“NKMax”), a Korean biotechnology company, out of bankruptcy, previously disclosed in the Current Reports on Form 8-K filed on June 20, 2025 and December 2, 2024.”
Published 9 Sep 2025
Open the sourceWhat happened
NKGen Biotech, Inc. completed its acquisition of a majority equity stake in NKMax Co., Ltd., a Korean biotechnology company, out of bankruptcy. The transaction gives NKGen control of NKMax’s global manufacturing infrastructure, intellectual property and exclusive commercialization rights. [01]
The acquisition was supported by approximately $17 million in funding. NKMax focuses on advancing immune cell therapies and also develops and commercializes bioreagents and immunodiagnostic kits. [01]
The source
Everything on this page comes from the source below, quoted word for word.
NKGen Biotech takes control of NKMax in completed acquisition
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly